Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Harvard Business School
Healthtrust
Fish and Richardson
Boehringer Ingelheim
Federal Trade Commission
Baxter
Novartis
Medtronic
Cantor Fitzgerald

Generated: January 21, 2018

DrugPatentWatch Database Preview

ULTRAM Drug Profile

« Back to Dashboard

When do Ultram patents expire, and when can generic versions of Ultram launch?

Ultram is a drug marketed by Janssen Pharms and Valeant Pharms and is included in two NDAs. There is one patent protecting this drug and three Paragraph IV challenges.

The generic ingredient in ULTRAM is tramadol hydrochloride. There are thirty-six drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the tramadol hydrochloride profile page.
Drug patent expirations by year for ULTRAM
Pharmacology for ULTRAM
Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for ULTRAM

US Patents and Regulatory Information for ULTRAM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms ULTRAM tramadol hydrochloride TABLET;ORAL 020281-002 Mar 3, 1995 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Valeant Pharms ULTRAM ER tramadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 021692-002 Sep 8, 2005 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Janssen Pharms ULTRAM tramadol hydrochloride TABLET;ORAL 020281-001 Mar 3, 1995 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Valeant Pharms ULTRAM ER tramadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 021692-001 Sep 8, 2005 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Pharms ULTRAM ER tramadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 021692-003 Sep 8, 2005 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ULTRAM
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 300 mg ➤ Subscribe 9/25/2007
➤ Subscribe Extended-release Tablets 200 mg ➤ Subscribe 3/28/2007
➤ Subscribe Extended-release Tablets 100 mg ➤ Subscribe 1/8/2007

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
AstraZeneca
Accenture
Johnson and Johnson
Farmers Insurance
McKinsey
Healthtrust
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot